New report highlights the value of near patient testing
The British In Vitro Diagnostics Association (BIVDA) has released a report today titled “Near Patient Testing – The Value Story”.
The report describes the value of near patient testing in the delivery of care to patients, allowing timely diagnosis at the bedside, in general practice, or in the community, and provides insight into the major role it can play in redesigning services around the needs of the patient.
Doris-Ann Williams, BIVDA’s Chief Executive, said: “Near patient testing provides an efficient and effective way of diagnosing, treating and managing conditions at the point of care. Against a background of continued pressure on the NHS’s time and resources and evolving healthcare needs, the IVD industry has an important role to play in supporting positive patient outcomes through testing innovations.”
Supported by a range of case studies, the publication covers a number of key impact areas, including the role and value of near patient testing in the diagnosis of sexually transmitted infections, in facilitating antimicrobial stewardship, in preventing unnecessary hospital admissions and in empowering patients to manage their own condition after diagnosis.
- For an electronic copy of the Near Patient Testing – The Value Story report, click here.
- BIVDA is the national industry association for the manufacturers and distributors of IVD products in the UK. We currently represent more than 95% of the industry and over a hundred organisations ranging from British start-up companies to UK subsidiaries of multinational corporations. BIVDA members currently employ over 8,500 people in the UK, with a total industry turnover of approximately £920 million.
- Media Contact: Nunzia Florio, External Affairs Manager
Tel. 020 7647 9755